Human Fc gamma RIIA / CD32a (R167) Protein, His Tag (MALS & BLI verified)
分子別名(Synonym)
CD32a,FCGR2A,CD32,FCG2 ,FCGR2A1,IGFR2
表達(dá)區(qū)間及表達(dá)系統(tǒng)(Source)
Human CD32a (R167), His Tag (CDA-H5221) is expressed from human 293 cells (HEK293). It contains AA Ala 36 - Ile 218 (Accession # P12318-1 (H167R)).
Predicted N-terminus: Ala 36
蛋白結(jié)構(gòu)(Molecular Characterization)

This protein carries a polyhistidine tag at the C-terminus.
The protein has a calculated MW of 21.6 kDa. The protein migrates as 25-35 kDa when calibrated against Star Ribbon Pre-stained Protein Marker under reducing (R) condition (SDS-PAGE) due to glycosylation.
內(nèi)毒素(Endotoxin)
Less than 1.0 EU per μg by the LAL method / rFC method.
純度(Purity)
>95% as determined by SDS-PAGE.
>90% as determined by SEC-MALS.
制劑(Formulation)
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with trehalose as protectant.
Contact us for customized product form or formulation.
重構(gòu)方法(Reconstitution)
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
存儲(Storage)
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
-20°C to -70°C for 12 months in lyophilized state;
-70°C for 12 months under sterile conditions after reconstitution.



背景介紹
IgG Fc段受體(FcγR)是免疫球蛋白超家族成員,在免疫反應(yīng)的激活或抑制中發(fā)揮作用。目前已確認(rèn)三類人類Fcγ受體:RI(CD64)、RII(CD32)和RIII(CD16),這些受體可產(chǎn)生多種亞型。
人類FcγRII/CD32包含三種基因亞型(A、B、C),小鼠則僅有FcγRII B(CD32B)。CD32是低親和力IgG受體,其中激活型亞型CD32A表達(dá)于單核細(xì)胞、中性粒細(xì)胞、血小板及樹突細(xì)胞表面。該受體廣泛分布于多種免疫細(xì)胞(巨噬細(xì)胞、中性粒細(xì)胞、嗜酸性粒細(xì)胞、血小板、樹突細(xì)胞及朗格漢斯細(xì)胞),這些細(xì)胞可能同時(shí)共表達(dá)攜帶抑制性ITIM結(jié)構(gòu)域的受體,并被特定配體共結(jié)合。
CD32A通過配體結(jié)合傳遞激活信號,觸發(fā)包括細(xì)胞溶解、吞噬作用、脫顆粒及細(xì)胞因子產(chǎn)生在內(nèi)的炎癥反應(yīng)。此類反應(yīng)可受共表達(dá)抑制性受體(如CD32B)的信號調(diào)控,且信號強(qiáng)度取決于激活型與抑制型受體的表達(dá)比例。
關(guān)鍵字: Fc gamma RIIA;Fc gamma RIIA蛋白;CD32a重組蛋白;ACRO;百普賽斯;
百普賽斯集團(tuán)ACROBiosystems Group(股票代碼:301080)是成立于2010年的跨國生物科技公司,是為全球生物醫(yī)藥、健康產(chǎn)業(yè)領(lǐng)域提供關(guān)鍵生物試劑產(chǎn)品及解決方案的行業(yè)平臺型基石企業(yè)。2021年在創(chuàng)業(yè)板上市。百普賽斯集團(tuán)業(yè)務(wù)遍布全球,橫跨亞洲、北美洲、歐洲,在中國、美國、瑞士等12個(gè)城市設(shè)有辦公室、研發(fā)中心及生產(chǎn)基地。目前累計(jì)服務(wù)客戶超6000家,與全球Top 20醫(yī)藥企業(yè)均建立了長期、穩(wěn)定的合作伙伴關(guān)系。集團(tuán)旗下?lián)碛衅放艫CROBiosystems百普賽斯、bioSeedin柏思薈、Condense Capital墾拓資本和ACRODiagnostics百斯醫(yī)學(xué)等。